Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma

BJU International

Volumn 108, Issue 3, 2011, Pages 355-359

  Kirrander, Peter ^a   Kolaric, Aleksandra ^a   Helenius, Gisela ^a   Windahl, Torgny ^a   Andrén, Ove ^a   Stark, Jennifer Rider ^a,d   Lillsunde Larsson, Gabriella ^a   Elgh, Fredrik ^b,c   Karlsson, Mats ^a,b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

human papillomavirus; penile carcinoma; polymerase chain reaction; prognostic markers

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; COHORT ANALYSIS; ETHNIC GROUP; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; PENIS CARCINOMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SWEDISH; TUMOR DIFFERENTIATION; VIRUS DETECTION;

ADULT; AGED; AGED, 80 AND OVER; DNA, VIRAL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENILE NEOPLASMS; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SWEDEN;

EID: 79960606053     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09770.x     Document Type: Article

References (25)

1. Trimble CL, Frazer IH,. Development of therapeutic HPV vaccines. Lancet Oncol 2009; 10: 975-80
2. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L,. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 (Suppl 3): S3/1-10
3. Baseman JG, Koutsky LA,. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32 (Suppl 1): S16-24 (Pubitemid 40332585)
4. zur Hausen H,. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009; 384: 260-5
5. Munoz N,. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000; 19: 1-5
6. Gillison ML, Chaturvedi AK, Lowy DR,. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113 (Suppl): 3036-46
7. Persson B, Sjodin JG, Holmberg L, Windahl T,. The national penile cancer register in Sweden 2000-2003. Scand J Urol Nephrol 2007; 41: 278-82 (Pubitemid 47357187)
8. Muneer A, Kayes O, Ahmed HU, Arya M, Minhas S,. Molecular prognostic factors in penile cancer. World J Urol 2009; 27: 161-7
9. Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, de Sanjose S,. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009; 62: 870-8
10. Kayes O, Ahmed HU, Arya M, Minhas S,. Molecular and genetic pathways in penile cancer. Lancet Oncol 2007; 8: 420-9 (Pubitemid 46621770)
11. Lindh M, Gorander S, Andersson E, Horal P, Mattsby-Balzer I, Ryd W,. Real-time Taqman PCR targeting 14 human papilloma virus types. J Clin Virol 2007; 40: 321-4 (Pubitemid 350152007)
12. Backes DM, Kurman RJ, Pimenta JM, Smith JS,. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009; 20: 449-57
13. Krustrup D, Jensen HL, van den Brule AJ, Frisch M,. Histological characteristics of human papilloma-virus-positive and -negative invasive and in situ squamous cell tumours of the penis. Int J Exp Pathol 2009; 90: 182-9
14. Harper DM,. Current prophylactic HPV vaccines and gynecologic premalignancies. Curr Opin Obstet Gynecol 2009; 21: 457-64
15. Block SL, Nolan T, Sattler C, et al,. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118: 2135-45 (Pubitemid 46393698)
16. Petaja T, Keranen H, Karppa T, et al,. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009; 44: 33-40
17. Giuliano AR,. Human papillomavirus vaccination in males. Gynecol Oncol 2007; 107 (Suppl 1): S24-6 (Pubitemid 47559076)
18. Scheiner MA, Campos MM, Ornellas AA, Chin EW, Ornellas MH, Andrada-Serpa MJ,. Human papillomavirus and penile cancers in Rio de Janeiro, Brazil: HPV typing and clinical features. Int Braz J Urol 2008; 34: 467-74; discussion 75-6
19. Bezerra AL, Lopes A, Santiago GH, Ribeiro KC, Latorre MR, Villa LL,. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001; 91: 2315-21 (Pubitemid 32552817)
20. Lont AP, Kroon BK, Horenblas S, et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer 2006; 119: 1078-81 (Pubitemid 44116916)
21. Gregoire L, Cubilla AL, Reuter VE, Haas GP, Lancaster WD,. Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. J Natl Cancer Inst 1995; 87: 1705-9
22. Pizzocaro G, Algaba F, Horenblas S, et al,. EAU penile cancer guidelines 2009. Eur Urol 2010; 57: 1002-12
23. Ravi R,. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol 1993; 72 (5 Pt 2): 817-9 (Pubitemid 24000147)
24. Hegarty PK, Kayes O, Freeman A, Christopher N, Ralph DJ, Minhas S,. A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines. BJU Int 2006; 98: 526-31 (Pubitemid 44185869)
25. Leijte JA, Kroon BK, Valdes Olmos RA, Nieweg OE, Horenblas S,. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol 2007; 52: 170-7 (Pubitemid 46803023)